



PART I: Training in community pharmacies

By

Dr. Anes Abdulwahid Thabit

Contributors

Members of Academic Staff of Pharmacy Department –Medical sciences college-Al-Razi University, Yemen

| Name of Trainee | ÄL-RAZI UNIVERSI |
|----------------------|------------------|
| Academic year | |
| Supervisor Name/ Sig | |



Contents

| Pre | face | 2 |
|------|-------------------------------------|----|
| I. | Introduction | 3 |
| II. | Details of field of training | 8 |
| III. | OTC medications | 9 |
| IV. | Prescription only medications | 28 |
| ٧. | Prescriptions checking | 36 |
| VI. | Pharmaceutical agents/manufacturers | 46 |



PREFACE

Filed training, together with theoretical and practical parts, are the fundamental parts of the pharmacy bachelor program adopted by the pharmacy department –medical sciences college, Al-Razi university.

The filed-training booklet is prepared with the intention to provide orientation to trainees and supervisors about various tasks to be performed and/or observed in different disciplines during the training period. The main goal of the training is to acquire necessary practical skills different pharmacy profession fields.

Dr. Anes Abdulwahid Thabit





I. INTRODUCTION

Pharmacy Bachelor Program

| General information | |
|------------------------------------------------|----------------------------------------------|
| The profession for which the program prepares | Pharmacy |
| the students | |
| Program name & scientific degree awarded | Pharmacy Bachelor |
| The entity awarding the degree | Medical sciences college |
| The academic department responsible for the | Pharmacy department |
| program | |
| | Medical sciences College (Medical laboratory |
| Other departments participating in the program | dept., applied medical sciences dept.), |
| | Computer sciences & IT College (Computer |
| | sciences dept.,) |
| Language of the study | English |
| Attendnace | Compulsory attendance (minimum 75 %) |
| Facility of program execution | The university |
| Study type | Semester type - Credit hours |
| Study duration | 5 academic years consisting of 10 academic |
| Study duration | semesters |
| Program Coordinator | Dr/ Anes Thabit |

Program mission & aims

Mission

The program intends to offer remarkable curriculum in pharmacy characterized with modernity and comprehension and focusing on development of both the knowledge and skill aspects of students in order to ensure graduation of highly qualified pharmacists who are able to provide high pharmaceutical services to their communities.

Aims

- 1. To Provide the students with scientific knowledge in basic sciences and pharmaceutical sciences including the modern ones that are essential to realize their duties and activities as pharmacists.
- 2. To develop the intellectual, professional and practical skills of the students to make them able to perform all types of pharmacy-related works.
- 3. Enhancing the transferable skills of the students to perform pharmacy profession with respect to their colleagues, patients and community and in compliance to the profession ethics and laws



Field-training Specifications

Introduction

The filed training in pharmacy is considered as essential part in modern pharmacy academic educational programs. This part together with the theoretical and practical parts are indispensable in pharmacy programs. It is designed to provide the student with an opportunity to integrate and apply previously acquired knowledge and technical skills in actual pharmacy field settings. With collaboration of experienced pharmacy Professionals and under supervision of the pharmacy department, the student can learn more about various tasks related to pharmacist carriers.

The filed-training provides applied learning experiences and skills which make the student able to practice and acquire the following skills

A- Professional skills

- 1. community-pharmacy skills such pharmacy organization, documentation and OTC drug selection.
- 2. hospital -pharmacy skills such drug distribution, prescription checking, medical store management and handling of controlled drugs.
- 3. Clinical -pharmacy skills such sharing in medical rotation, understanding patient medical files, case studies, therapy designing and monitoring.
- 4. Industrial pharmacy skills such as storage and quality control assessment of raw materials and finished products, research and development of dosage forms and safe and effective large- scale production of drug products.

B- Transferable Skills

- 1. Creative problem-solving
- 2. Intimate team work
- 3. Precise reporting





Training Specifications

I- Trainee eligibility criteria

The training starts at the second semester of the 4th academic year. Therefore, to be eligible eligible as trainee, the pharmacy BC student should have successfully passed all prerequisite courses of the program.

II- Filed -training plan

The period for the filed-training is composed of 182 actual field hours. These hours are divided into 2 courses: pharmacy training I (120 hours) and pharmacy training II (72 hours). The first course starts at the 4th week of the 2nd semester/4th academic year and lasts till the 13th week of that semester. The second course starts at the 3rd week of 1st semester/5th academic year and lasts till the 11th week of that semester. The plan of training is illustrated in the following table.

| Table 1. Pla | Table 1. Plan of pharmacy filed-training | | | | | | | | |
|-----------------------|------------------------------------------|-----------------------------------------|----------------|----------------------------------------------|----------------|-------------------------------------------------------------|----------------------------------------------------------------------------------------------|--|--|
| Course | Field hours | Semester/Year | Weeks due | Period specified (Months) | Hours/ week | Fields | Disciplines | | |
| Pharmacy training I | 120 | 2 nd /4 th year | Weeks 4-13 | 2.5 | 12 | Community pharmacies | Pharmacy practice skills | | |
| Pharmac y training | 20 | 1 st / 5 th years | Weeks 3- 6 | 1 | 5 | Hospitals | Hospital pharmacy | | |
| II | 30 | | Weeks 7- 11 | 1 | 6 | | Pharmaceutical clinical care | | |
| | 12 | | Week s 6-9 | 1 | 4 | Yemeni drug plants (at least 2 drug factories) | Industrial pharmacy, Pharmaceutics , Pharmaceutical analysis, pharmaceutical quality control | | |
| Total | 182 | | <u> </u> | <u> </u> | <u> </u> | | - | | |

PHARMACY BACHELOR

Field training Booklet III- Trainee' responsibilities



During training period, every trainee has to demonstrate following responsibilities:

- 1. Demonstrate good behavior during and after practicing the training.
- 2. Complete all tasks of training.
- 3. Commit to instructions of the training supervisor.
- 4. Nerve commit cheating or lying by utilizing his/her colleague works
- 5. Adhere to the times of training.
- 6. Keep the integrity and calmness of the training field
- 7. Obey the directions of the field principle
- 8. Respect rules and policies of the field
- 9. Establish good working relationships with his/her colleagues and other personnel in the field.

Any trainee who fails to demonstrate any of those responsibilities as judged by the supervisor shall considered failed in the training.

IV- Training supervision, monitoring and assessment

The trainee works will be supervised by the "**training supervisor**" who is a member of pharmacy department staff. The supervisor has the right to monitor and visit training sites regularly and to meet the trainee and the principle in the training field to discuss the progress of training. The supervisor should assess the attendance and attitude of the trainee during those visits. The trainee assessment is demonstrated in the following table

| Table 3. Assessment of trainee in pharmacy filed-training | | | | | |
|-----------------------------------------------------------|------------------------------------------|------|------------------------------------------------|--|--|
| No. | Assessment Method | Mark | Weight % n of Total course Assessment | | |
| 1 | Trainee attendance (by the supervisor) | 10 | 10% | | |
| 2 | Filed-training tasks (by the supervisor) | 60 | 30 % | | |
| 3 | Final oral exam (By the committee) | 30 | 60% | | |
| Total | | 100 | 100% | | |



• Attendance

The cut off of attendance is 75% of the credit hours of training. Any trainee who doesn't attain the cut off marks shall FAIL in the training whatever the excuses he/she present

• Filed training tasks

- All tasks should be completed by the trainee within the specified time of training
- o The supervisor shall assess those tasks for every trainee.
- o For training in community pharmacy and hospitals, after completion the training, The trainee should provide signed and stamped certificates from those field. The certificate should clearly mention the name and owner/manager of the site and duration of training which should be in accordance to the period specified.

• Final oral exam (By the committee)

- The committee is composed on the supervisor and one of the academic staff of the department.
- Assessment is as flows
 - ❖ Supervisor 10 %
 - ❖ Academic member 20 %
- The exam is of Oral pattern.



II. DETAILS OF THE FIELD OF TRAINING

| Name of pharmacy: |
|----------------------------|
| Address of pharmacy: City |
| Telephone |
| Pharmacy Principle; Mobile |

Details of the Community pharmacy where the training has been accomplished.



III. OTC MEDICATIONS

Note: for injectable medications, write IM, IV, SC near to the adult dose

A. OTC analgesics

Task 1: Complete the following table of OTC analgesics with different generic names

| (i) Table | et or capsules OT(| C analgesics | | | |
|---------------|-----------------------------------------|----------------------|-----------------------------------------|---------------|-------------------------------------------------|
| Generic name | Trade name, Manuf. Company, | | Strength & | adult Dose | Black box or |
| | country | | dosage form | (e.g. 1 x3) | Contraindications |
| | Original | other | uosuge rorini | (e.g. 1 110) | |
| 1 Paracetamol | Panad ol GSK, UK | Amol Shifaco, YEM | 500 mg tab. | 1x3 | Hypersensitivity Sever active liver diseases |
| 2 | | | | | ••••• |
| | | | | | ••••• |
| 3 | | | | | ••••• |
| | | | | | • • • • • • • • • • • • • • • • • • • • |
| 4 | | | | | ••••• |
| | | | | | ••••• |
| 5 | | | | | ••••• |
| | | | | • • • • • | ••••• |
| 5 | ••••• | | | | ••••• |
| | | | | | ••••• |
| | | | | | |
| _ | • • • • • • • • • • • • • • • • • • • • | | • • • • • • • • • • • • • • • • • • • • | • • • • • | ••••• |
| 3 | • • • • • • • • • • • • • • • • • • • • | | | | •••• |
| | ••••• | | | | ••••• |
|) | • • • • • • • • • • • • • • • • • • • • | | | | ••••• |
| | • • • • • • • • • • • • • • • • • • • • | | | •••• | ••••• |
| 10 | | | | | ••••• |
| (10) | | | | •••• | ••••• |
| · · · | adult OTC analge | sic | | | |
| 1 | | | | | •••• |
| | ••••• | | | | ••••• |
| 2 | | | | | ••••• |
| _ | • • • • • • • • • • • • • • • • • • • • | | | | ••••• |
| | | | | | ••••• |
| (***) | | | | • • • • • | ••••• |
| (iii) I.V. a | adult OTC analges | sic | | | |
| 1 | | | | | ••••• |
| | | | | | ••••• |
| 2 | ••••• | ••••• | ••••• | ••••• | |
| | • • • • • • • • • • • • • • • • • • • • | | | •••• | • • • • • • • • • • • • • • • • • • • • |



| (iv) Adu | lt rectal OTC anal | gesic | | | |
|-----------------|-----------------------------------------|-----------------------------|------------------------|-----------------------|--------------------------------------|
| Generic name | Trade name, Manu country original | other | Strength & dosage form | Adult dose e.g. (1x3) | Contraindications |
| 1 diclofenac Na | Voltarene Novartis, SWZ | Declophen Pharco, EGY | 100 mg Suppose. | 1x1 | CVS (M.I), GITR (PU), hypersentivity |
| 2 | | | | | ••••• |
| 3 | | | | | ••••• |
| (v) Oral | pediatric OTC a | nalgesic | | | |
| 1 | | | | | ••••• |
| 2 | | | | | ••••• |
| 3 | | | | | ••••• |
| (vi) Rect | al pediatric OTC a | nnalgesic | | | |
| 1 | | | | | |
| 2 | | | | | |
| 3 | | | | | ••••• |
| | | | | | ••••• |
| | ctable pediatric OT | C analgesic | | | |
| 1 | | | | | ••••• |
| 2 | | | | | ••••• |
| (viii) Topi | ical OTC analgesic | | | | |
| 1 | | | | | |
| 2 | | | | | |
| 3 | | | | | |
| 4 | | | | | ••••• |
| 5 | | | | | •••••• |
| | | | | | ••••• |
| 6 | ••••• | •••••• | ••••• | ••••• | ••••• |
| | | | | | |



Task 2: Select OTC analgesics Specific group of patients (Write TWO different generic

names, if any)

| Pediatr ic (Child) | Peptic ulcer | Pregna nt women | Lactating (breastfee d ing) women | Renal failure or Hemodialy si s | Hepat ic failur e | CV S (M. I) | Old people (Geriatri c) |
|--------------------------|--------------|-----------------------|--------------------------------------------|------------------------------------------|----------------------------|----------------------|----------------------------------|
| 1 | 1 | 1 | 1 | 1 Dose adjustment | 1 | 1 | 1 Dose adjustme nt |
| 2 age | 2 | 2 | 2 | 2 Dose adjustment | 2 | 2 | 2 Dose adjustme nt |

| 1. | What is the generic name of paracetamol in USA? |
|----|--------------------------------------------------------------------------------------------------------------------------------|
| 2. | Are NSAIDs contraindicated in bronchial asthma or should be used cautiously? |
| 3. | Can aspirin be used for children who have fever ? Why ? |
| 4. | Other than paracetamol, Which is better OTC analgesic for a lactating woman? |
| | In children, at what age diclofenac sodium can be used for children? |
| 6. | For a patient with sever toothache, what do you recommend? Why? (paracetamol - ketoprofen - paracetamol +caffeine) because |
| 7. | Is Solpadeine® an OTC analgesic? why? |
| 8. | A patient comes to the pharmacy suffering from myalgia ? what do you recommend ? |
| 9. | What is the best OTC analgesic for renal colic e.g. due to renal stone? |



B. OTC for GIT disorders

Task 4: Complete the following table of GIT OTC with different generic names

| (i) Neutralizing antacids for | | | | | | | | |
|-------------------------------|--------------------|----------------------|-------------------|-----------------------------------------|-------------|--|--|--|
| | (i) | Neutralizing a | antacias for | | | | | |
| simple hype | eracidity M.O.A: | | | | | | | |
| | | | | | | | | |
| Generic name | Trade name, Manu | if. Company, | Strength & | Adult dose | Contraindic | | | |
| | country | - 41 ·· | dosage form | e.g. (1x3) | ations | | | |
| 1 1' | original | other | | | | | | |
| 1sodium | ••••• | | | • • • • • • • • • • • • • • • • • • • • | ••••• | | | |
| 1 1 1 | | | | •••• | ••••• | | | |
| bicarbonate | | | | | ••••• | | | |
| | | | | | ••••• | | | |
| 2Aluminum | | | | | ••••• | | | |
| | | | | | ••••• | | | |
| hydroxide + | | | | | ••••• | | | |
| | | | | | ••••• | | | |
| magnesium | | | | | | | | |
| hydroxide | | | | | | | | |
| 3Aluminum | | | | | | | | |
| | | | | | ••••• | | | |
| hydroxide + | | | | | ••••• | | | |
| ľ | | | | | ••••• | | | |
| magnesium | | | | | | | | |
| hydroxide + | | | | | | | | |
| simethicone | | | | | | | | |
| 4 antacid + | | | | | | | | |
| 4 antacia + | | | | | ••••• | | | |
| | | | | | ••••• | | | |
| sodium | ••••• | | ••••• | | ••••• | | | |
| alginate | | | | | ••••• | | | |
| | H2 blockers for ga | | | | | | | |
| esophageal ref | lux (GERD) M.O.A | \: | | | | | | |
| •••••• | | ••••• | | | | | | |
| 1 | | | | | ••••• | | | |
| | | | | | ••••• | | | |
| | | | | | ••••• | | | |
| | | | | | ••••• | | | |
| 2 | | | | | | | | |
| | | | | | ••••• | | | |
| | | | | | ••••• | | | |
| | | | | | ••••• | | | |
| (iii) Inje | ctable H2 blockers | for gastritis and g | gastro esophagea | al reflux (GEF | RD) | | | |
| 1 | | | | | | | | |
| | | | | | ••••• | | | |
| | | | | | ••••• | | | |
| | | | | | •••••• | | | |
| (iv) Oral | Proton pump inhi | bitors (PPIs) for I | Peptic ulcer and | GERD | | | | |
| 1 | - 1000 pump mm | | - Spire areer and | | | | | |
| 1 | ••••• | ••••• | | | ••••• | | | |
| | | | | | ••••• | | | |



| | | | | | ••••• |
|-------|-------------------|----------------------|-----------------|------------|--------|
| 2 | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| 3 | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| 4 | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| _ | | | | | ••••• |
| 5 | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| () - | | 4 1 41 4 (PPT) | 0 70 /1 7 | 1 0777 | ••••• |
| | ctable Proton pum | p inhibitors (PPIs) | for Peptic ulce | r and GERD | |
| 1 | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| 2 | | | | ••••• | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| | | | | | |
| 2 | | | | | ••••• |
| 3 | | | | | ••••• |
| 3 | | | | | |
| 3 | | | | | |
| | | | | | •••••• |
| 4 | | | | | |
| | | | | | •••••• |
| | | | | | |



| | ness; M.O.A: | | | | |
|--------------------|--------------------------|-----------------------------------------|------------------------|-----------------------|-------------------|
| Generic name | Trade name, Manu country | ıf. Company, | Strength & dosage form | Adult dose e.g. (1x3) | Contraindications |
| | original | other | Ü | | |
| 1 | Dramamine | Dizinil | 50 | 1 x 30 | Hypersensi |
| Dimenhydrina | | Julphar, | mg | min. | tivity, |
| te | | UAE | Ta | before | asthma, |
| | | OTIL | b. | trip Then | neonates, |
| | | | 0. | 1 x 3 | · |
| | | | | 1 X 3 | nursing |
| <u> </u> | | | | | women |
| 2 | | | | ••••• | ••••• |
| | | | | •••• | ••••• |
| | | | | | ••••• |
| (- !!) O 1 | 1 14 A 4' 4' | / C • 4• 4 | 1 4 4 | • • • • • | • |
| | adult Antiemetics | | | ackness) : dop | amine |
| | O.A: | | ••••• | | |
| 1 | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| 2 | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| (viii) Oral | adult Antiemetics | (for vomiting not | due to motion s | ickness): | |
| serotonin antago | onists M.O.A: | • • • • • • • • • • • • • • • • • • • • | | | |
| 1 | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| (ix) Pedi | atric antiemetics | | | | |
| 1 | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| 2 | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| (x) Injec | ctable antiemetics | | | | |
| 1 | | | | | |
| | | | | | |
| | | | | | ****** |
| | | | | | ••••• |
| 2 | | | | | |
| | | | | | |
| 4 | | | | | |
| 4 | | | | | ••••• |



| (xi) Antispasmodics (Spasmolytics) for colic of GIT and urinary system 1: Anticholinergics M.OA.: | | | | | | | |
|---------------------------------------------------------------------------------------------------|----------------------------|-------|------------------|---------------|-------|--|--|
| 1 | | | | | ••••• | | |
| | | | | | ••••• | | |
| | | | | | ••••• | | |
| | | | | | ••••• | | |
| 2 | | | | | ••••• | | |
| | | | | | ••••• | | |
| | | | | | ••••• | | |
| | | | | | ••••• | | |
| 3 | | | | | ••••• | | |
| | | | | | ••••• | | |
| | | | | | ••••• | | |
| | | | | | ••••• | | |
| Anticholine | spasmodics (Spasn rgics | - | of GIT and uring | ary system 1: | Non- | | |
| 1 | | | | | ••••• | | |
| | | | | | ••••• | | |
| | | | | | ••••• | | |
| | | | | | ••••• | | |
| 2 | | | | | ••••• | | |
| | | | | | ••••• | | |
| | | | | | ••••• | | |
| | | | | | ••••• | | |
| 3 | | | | | ••••• | | |
| | | | | | | | |
| | | | | | ••••• | | |
| | ••••• | ••••• | | | ••••• | | |



| digestive en | spasmodic + zyme M.O.A: | | | | |
|-----------------------------------------|-----------------------------------------|-----------------------|------------------------|--------------------------|--------------------|
| | | | | | |
| Generic name | Trade name, Manu country | ıf. Company, | Strength & dosage form | Adult dose e.g. (1x3) | Contraindicat ions |
| | original | other | dosage form | C.g. (1A3) | 10113 |
| 1 | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| 2 | ••••• | | | | ••••• |
| | | | | •••• | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| analgesics M.O | spasmodics + O.A: | | | | |
| 1 | | | | | |
| 1 | | | | | ••••• |
| | *************************************** | | | ••••• | •••••• |
| | | | | | |
| 2 | | | | | |
| | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| diarrhea : Opiat | diarrheoals : symp es M.O.A: | | | | |
| 1 | | | | | ••••• |
| | ••••• | | | •••• | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| 2 | | | | | ••••• |
| | • • • • • • • • • • • • • • • • • • • • | | | | ••••• |
| | | | | | ••••• |
| () | | | | | ••••• |
| (xvi) Antio diarrhea : Adson | diarrheoals : symp bent M.O.A: | tomatic relief of | | | |
| 1 | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| (xvii) Laxati | ives: for constipation | on : Purgatives | | | |
| 1 | | | | | |
| • • • • • • • • • • • • • • • • • • • • | | | | | |



| | | | | | ••••• |
|--------------|----------------------|-----------------------------------------|-------|-------|--------|
| | | | | | ••••• |
| 2 | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| 3 | | | | | ••••• |
| | | | | ••••• | ••••• |
| | | | | | ••••• |
| 4 | | | | | ••••• |
| 4 | | | | ••••• | ••••• |
| | ••••• | | | ••••• | •••••• |
| | | | | | |
| (•••\ T | | | | | •••••• |
| (XVIII) Laxa | tives: for constipat | ion : osmotic agent | ts | | |
| M.OA.: | ••••• | • • • • • • • • • • • • • • • • • • • • | | | |
| 1 | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| 2 | | | | | ••••• |
| | | | | ••••• | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| 3 | | | | | ••••• |
| | | | | •••• | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| (i) Laxa | tives: for constipat | tion : stool softene | r | | |
| M.OA.: | | • • • • • • • • • • • • • • • • • • • • | | | |
| 1 | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| 2 | ••••• | ••••• | ••••• | ••••• | ••••• |
| | ••••• | ••••• | ••••• | •••• | ••••• |
| | | | | | ••••• |
| | | | | | |



| Generic name | Trade name, Manuf. Company, | | Strength & | Adult dose | Contraindic |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|----------------|-----------------------------------------|
| | country original | other | dosage form | e.g. (1x3) | ns |
| 1 | | | | | |
| 1 | | | | | |
| | | | | •••• | |
| | | | | | •••• |
| (xx) OTO | for | | | | |
| hemorrhoids: | Topical M.O.A: | | | | |
| ••••• | - | | | | |
| ••••• | | | | | |
| 1 | | | | | • • • • • • • • • • • • • • • • • • • • |
| | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| 2 | | | | | • • • • • • • • • • • • • • • • • • • • |
| | | | | | ••••• |
| | | | | | • • • • • • • • • • • • • • • • • • • • |
| | | | | | ••••• |
| 3 | | | | ••••• | • • • • • • • • • • • • • • • • • • • • |
| | | | | | ••••• |
| | | | | | |
| | | | | | ••••• |
| (xxi) OTO hemorrhoids: or | | | | | ••••• |
| | | | | | |
| hemorrhoids: or | | | | | |
| hemorrhoids: or | | | | | |
| hemorrhoids: or | | | | | |
| hemorrhoids: oi | | | | | |
| hemorrhoids: or | ral M.O.A: | | | | |
| hemorrhoids: or | ral M.O.A: | ions dvance ®) safe or b | ooth safe in preg | mancy? why | |
| hemorrhoids: or | ral M.O.A: Γ answer the quest Β) or (Gaviscon ac | dvance ®) safe or b | | | |
| hemorrhoids: or | ral M.O.A: Γ answer the quest Β) or (Gaviscon ac | lvance ®) safe or b | | | |
| _5: OTC for GIT | ral M.O.A: Γ answer the quest Β) or (Gaviscon ac | lvance ®) safe or b bicarbonate can c | | | |
| _5: OTC for GIT . Is (Gaviscon | ral M.O.A: Γ answer the quest Β) or (Gaviscon accontaining sodium | lvance ®) safe or b bicarbonate can c | ause 2 serious a | dverse effects | . What are |
| _5: OTC for GIT Is (Gaviscon@these effects? | ral M.O.A: Γ answer the quest Β) or (Gaviscon accontaining sodium nes to the pharmac | lvance ®) safe or b bicarbonate can c cy and tell you that | ause 2 serious a | dverse effects | . What are |
| 5: OTC for GIT . Is (Gaviscon) . Medications of these effects? . A patient con (epigastric patient) | ral M.O.A: Canswer the quest Output Output | bicarbonate can control talks and tell you that 15 days . What gr | ause 2 serious a | dverse effects | . What are |
| 5: OTC for GIT . Is (Gaviscon) . Medications of these effects? . A patient con (epigastric patient) | ral M.O.A: Γ answer the quest Β) or (Gaviscon accontaining sodium nes to the pharmac | bicarbonate can control talks and tell you that 15 days . What gr | ause 2 serious a | dverse effects | . What are |
| 5: OTC for GIT . Is (Gaviscon) . Medications of these effects? . A patient con (epigastric particular and an entralizing an en | ral M.O.A: Canswer the quest Output Containing sodium | bicarbonate can control of the contr | ause 2 serious a t he had been su oups you recom | dverse effects | . What are |
| 5: OTC for GIT. Is (Gaviscon these effects? A patient con (epigastric para neutralizing and | ral M.O.A: Canswer the quest Containing sodium containing sodium nes to the pharmachin) for more than antacid, H2 blocker | bicarbonate can control of the contr | ause 2 serious a t he had been su oups you recom | dverse effects | . What are |
| 5: OTC for GIT. Is (Gaviscon these effects? A patient con (epigastric pa neutralizing a | ral M.O.A: Canswer the quest Containing sodium containing sodium nes to the pharmachin) for more than antacid, H2 blocker | bicarbonate can control of the contr | ause 2 serious a t he had been su oups you recom | dverse effects | . What are |



medication?

7. Is (metronidazole) an antidirrhoeal? Is it OTC?

8. (Regulate®) is a chocolate chewable tablets used for constipation. What is the generic name of this product? Is it a (medication) or (a poison)?

9. What are the drugs in (Epirax®)? what type of disease it is used for? Is it OTC? Why? Give another medication that can be used as alternative for that Epirax?

10. Drotaverine (Nospa)® is a very commonly prescribed antispasmodic in Yemen but considered illegal in USA and Europe. Why?

11. Enumerate 4 laxatives that can cause severe intestinal colic



Task 6: GIT OTC for Specific group of patients (Write generic names)

| OTC for GIT | Pediat ric (Child | Pregna nt women | Lactating (breastfe edi ng) women | Ren al failu re | Hepa tic failur e | CVS disease | Old people (Geriatr ic) |
|-----------------------------|-------------------------|-----------------------|-----------------------------------|--------------------------|----------------------------|----------------|-------------------------|
| | | | mg) women | | | | <i>(</i> |
| Neutraliz ing Antacid | age | | | Dose adjustm | | | Dose adjustm |
| | | | | ent | | | ent |
| H2 blockers | | | | Dose | | | Dose |
| | age | • | | adjustm ent | | | adjustm ent |
| | ••••• | | | | | | |
| PPIs | | | | Dose | | | Dose |
| | age | | | adjustm ent | | | adjustm ent |
| | | | | | | | |
| Antiemetic | | | | Dose | | | Dose |
| | age | | | adjustm ent | | | adjustm ent |
| | | | | | | | |
| Anti- motion | | | | Dose | | | Dose |
| sickness | age | | | adjustm ent | | | adjustm ent |
| | | | | | | | |
| Antisapsmo dic | | | | Dose | | | Dose |
| | age | | | adjustm ent | | | adjustm ent |
| | | | | | | | |



| Antidiarrhe al | age | | Dose adjustm ent | | Dose adjustm ent |
|-------------------|-----|------|------------------------|-----------|------------------------|
| Laxative | age | | Dose adjustm ent | ••••• | Dose adjustm ent |



C. OTC for Respiratory disorders

Task 7: Complete the following table of respiratory OTC with different generic names

| 4huaa4 . I aa | rongog M O A | (i) OTC fo | or sore | | | |
|---------------------------------------------|-----------------------------------------|------------|------------------------|-----------------------|--------------------|--|
| throat: Loz | zenges M.O.A: | | | | | |
| Generic name | Trade name, Manu country original | | Strength & dosage form | Adult dose e.g. (1x3) | Contraindicat ions | |
| 1 | | | | | | |
| 2 | | | | | | |
| throat: buccal | for sore spray M.O.A: | | | | | |
| 1 | | | | | | |
| throat: Gargles | C for sore M.O.A: | | | | | |
| 1 | | | | | | |
| 2 | | | | | | |
| 3 | | | | | | |
| (iv) Antihistamine 1 : sedative oral M.O.A: | | | | | | |
| | | | | | | |



| (v) Anti | histamine 1 : Non-s | sedative ; oral | | | |
|------------------|---------------------|-------------------|----------------|--------------|-----------|
| 1 | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| 2 | | | | | ••••• |
| | | | | •••• | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| 3 | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| 4 | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| | ctable antihistamin | e 1 | | | |
| 1 | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| | | Topical (nasal | | | |
| drop or nasal sp | ray) M.O.A: | | | | |
| ••••• | | •••• | | | |
| 1 | | | | | ••••• |
| | | | | •••• | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| 2 | | | | | ••••• |
| | | | | •••• | ••••• |
| | | | | | ••••• |
| (•••) > > 7 | | | 7 | | •••••• |
| | l decongestant +_ a | antihistamine It: | Topical (nasa | drop or nasa | al spray) |
| 1 | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| 2 | ••••• | ••••• | ••••• | ••••• | ••••• |
| | ••••• | ••••• | ••••• | •••• | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |



| (ix) Nasa | ll decongestant + ai | ntihistamine 1; or | al | | |
|---------------------------------|-------------------------------|--------------------|------------------------|-----------------------------------------|-------------|
| Generic name | Trade name, Manu | f. Company, | Strength & | Adult dose | Contraindic |
| | country | | dosage form | e.g. (1x3) | ations |
| | original | Other | | | |
| 1 | | | | | |
| | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| 2 | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| 3 | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| () | • . • | • • | | | ••••• |
| | nistamine 1 + analg | esic; oral | ı | | |
| 1 | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| (•) | | | | | ••••• |
| , , | nistamine 1 + analg | esic + nasal decon | gestant ; oral | | |
| 1 | | | | | ••••• |
| | | | | ••••• | ••••• |
| | | | | | ••••• |
| • | | | | | ••••• |
| 2 | | | | • • • • • • • • • • • • • • • • • • • • | ••••• |
| | | | | ••••• | ••••• |
| | | | | | ••••• |
| (wii) Dadi | | 1 | ~ 4 ~~ 4 | | ••••• |
| | atric antihistamine | 1 + nasai deconge | stant | | |
| 1 | | | | • • • • • • • • • • • • • • • • • • • • | ••••• |
| | | | | ••••• | ••••• |
| | | | | | ••••• |
| (viii) Dodi | | 1 magal daganga | gtant | | ••••• |
| (xiii) Pedia | atric antihistamine | 1 + nasai deconge | Stant | | |
| 1 | | | | | ••••• |
| | | | | ••••• | ••••• |
| | | | | | ••••• |
| (•) = = = | • 4• 6 4 | | | | ••••• |
| (xiv) Medi ; Mucolytic plair | ications for wet count M.O.A: | ıgh | | | |
| 1 | | | | | |
| 1 | ••••• | ••••• | | | |



| | | | | | ••••• |
|-----------------------------------------|-------------------------------|--------------------|----------------|----------------|----------|
| | | | | | ••••• |
| 2 | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| (xv) Med + bronchodilator | ications for wet cours M.O.A: | ugh; Expectorants | i | | |
| • • • • • • • • • • • • • • • • • • • • | ••••• | •••• | | | |
| 1 | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| 2 | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| (!) 75.7 | • • • • • • | | | | |
| | ications for wet co | ugh ; Expectorants | + bronchodilat | tors + antihis | tamine 1 |
| 1 | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| _ | | | | | ••••• |
| 2 | | | | | ••••• |
| | | | | •••• | ••••• |
| | | | | | ••••• |
| (!!) 3.5. 11 | | | | | ••••• |
| | ations for wet cou | gh ; Herbal | | | |
| 1 | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| _ | | | | | ******** |
| 2 | ••••• | ••••• | ••••• | ••••• | ••••• |
| | ••••• | ••••• | ••••• | •••• | ••••• |
| | | | | | ••••• |
| | l . | | | I | |



| (xviii) Antitussives (for dry cough) ; containing codeine M.O.A: | | | | | | |
|-------------------------------------------------------------------|------------------------------|-----------------------------------------|-------------|------------|-----------------------------------------|--|
| | | | | | | |
| Generic name | Trade name, Manu | f. Company, | Strength & | Adult dose | Contraindication | |
| | country | • • | dosage form | e.g. (1x3) | S | |
| | original | Other | | | | |
| 1 | | | | | | |
| | | | | | | |
| | | | | | ****** | |
| | | | | | ••••• | |
| 2 | | | | | ••••• | |
| 4 | | • • • • • • • • • • • • • • • • • • • • | | | ••••• | |
| | | | | •••• | ••••• | |
| | | | | | ••••• | |
| | | | | | ••••• | |
| cough) ; opoids I | tussives (for dry M.O.A: | | | | | |
| 1 | | | | ••••• | ••••• | |
| | | | | | ••••• | |
| | | | | | ••••• | |
| | | | | | ••••• | |
| 2 | | | | | ••••• | |
| | | | | | ••••• | |
| | | | | | • • • • • • • • • • • • • • • • • • • • | |
| | | | | | •••• | |
| 3 | | | | | ••••• | |
| | | | | •••• | | |
| | | | | | | |
| | | | | | | |
| antihistamin | •••••• | | | | | |
| 1 | ••••• | | | ••••• | ••••• | |
| | ••••• | ••••• | | •••• | ••••• | |
| | | | | | ••••• | |
| _ | | | | | ••••• | |
| 2 | | | | | ••••• | |
| | | | | •••• | ••••• | |
| | | | | | ••••• | |
| | | | | | ••••• | |
| (xxi) Pedia | atric medications fo | or wet cough | | | | |
| 1 | | | | | | |
| | | | | | | |
| | ••••• | ••••• | | •••• | ••••• | |
| | | | | | ••••• | |



| 2 | | | | | ••••• |
|---------------|----------------------------------------------------------------------|---------------------|------------------|------------------|------------------|
| | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| (xxii) Pediat | tric medications for | wet cough | | | |
| 1 | | | | | ••••• |
| | | | | •••• | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| 2 | ••••• | ••••• | ••••• | ••••• | ••••• |
| | ••••• | ••••• | ••••• | •••• | ••••• |
| | | | | | ••••• |
| Task8: Answer | | | | | ••••• |
| 2. A patien | 1 2 medications for 1 thas (sneezing) + (1 riate OTC medicati | (nasal redness)+ (r | hinorrhea; flu) | . Recommend | l one |
| 3. Some ph | narmacists recomm | end Vitamin C wi | th medications o | of cold . Is tha | at correct? why? |
| | ation containing (d gh, wet cough, or b | |) + (Guaifenesin |). Is it indica | ted for |
| 5. Why are | e oral nasal decong | estants not recomr | mended in patie | nt having a C | CVS disease? |
| 6. What ar | e the drugs for dry | cough and wet co | ugh that are not | t approved by | y FDA ? |



Task 9: Respiratory OTC for Specific group of patients (Write generic names)

| OTC for GIT | Pediatric | Pregnant | Lactating | Renal | Hepatic | CVS | Old people |
|----------------------------|-----------|----------|--------------|--------------------|---------|---------|--------------------|
| | (Child) | women | (breastfeedi | failure | failure | disease | (Geriatric) |
| | | | ng) women | | | | |
| Sore throat | | | | Doso | | | |
| | age | • | | Dose adjustment | | | Dose adjustment |
| | | | | | | | |
| Antihistamine | | | | | | | |
| | age | • | | Dose adjustment | | | Dose adjustment |
| | | | | | | | |
| Nasal | | | | Dose | | | Dose |
| decongestant | age | • | | adjustment | | | adjustment |
| | | | | | | | |
| Anticough | | | | Dose | | | Dose |
| | age | • | | adjustment | | | adjustment |
| | | | | | | | |
| Expectorant | | | | Dose | | | Dose |
| | age | • | | adjustment | | | adjustment |
| | | | | | | | |
| Mucolytic | | | | Dose | | | Dose |
| | age | | | adjustment | | | adjustment |
| | | | | | | | |
| For cough + bronchodilator | | | | Dose | | | Dose |
| | age | | | adjustment | | | adjustment |
| | | | | | | | |



D. OTC for Dermatologic disorders Task 10: Complete the following table of TOPICAL dermatologic OTC with different gene

| Generic name | Trade name, Man | | Strength & | Adult dose | Contraind |
|-----------------------------------------|--------------------------------------|--------------------|-------------|------------|-----------|
| | country original | Other | dosage form | e.g. (1x3) | ations |
| ••••• | | | | | ••••• |
| | | | | | ••••• |
| | | | | | |
| • • • • • • • • • • • • • • • • • • • • | | | | | |
| | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| ••••• | | | | | |
| | | | | | |
| | | | | | ••••• |
| | | | | | ••••• |
| • • • • • • • • • • • • • • • • • • • • | | | | | |
| ••••• | | | | •••• | ••••• |
| | cal antibacterial (I | PLAIN) for topical | | | •••••• |
| (ii) Topi bacterial infec | cal antibacterial (I | | | | |
| (ii) Topi bacterial infec | cal antibacterial (l tions M.O.A: | | | | |
| (ii) Topi bacterial infec | cal antibacterial (l | ••••• | T | | |
| (ii) Topi bacterial infec | cal antibacterial (l tions M.O.A: | | | | |
| (ii) Topi bacterial infec | cal antibacterial (l tions M.O.A: | | | | |
| (ii) Topi bacterial infec | cal antibacterial (l tions M.O.A: | | | | |
| (ii) Topi bacterial infec | cal antibacterial (l | | | | |
| (ii) Topi bacterial infec | cal antibacterial (l | | | | |
| (ii) Topi bacterial infec | cal antibacterial (l | | | | |
| (ii) Topi bacterial infec | cal antibacterial (l | | | | |
| (ii) Topi bacterial infec | cal antibacterial (l | | | | |
| (ii) Topi bacterial infec | cal antibacterial (l | | | | |
| (ii) Topi bacterial infec | cal antibacterial (I | | | | |



| 1 | | | | | ••••• |
|-----------|----------------------|---------------------|-----------|-------|-------|
| | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| 2 | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| 3 | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| (4) | | | | | ••••• |
| | cal corticosteroid - | - antibacterial | | | |
| 1 | | | | | ••••• |
| | | | | •••• | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| 2 | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| () | | | | | ••••• |
| | cal corticosteroid - | - antifungal | | | |
| 1 | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| 2 | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| (•) TD • | 1 4 4 1 | 400 1 40 | | | ••••• |
| | cal corticosteroid - | + antifungal + anti | bacterial | | |
| 1 | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| 2 | ••••• | ••••• | ••••• | ••••• | ••••• |
| | ••••• | ••••• | ••••• | •••• | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |



| (ix) Topi | cal preparations fo | or Burn (other tha | an corticosteroid | ls and | |
|-------------------|---------------------------------------|-----------------------------------------|-------------------|------------|------------------|
| antibacteria | als) M.O.A: | • • • • • • • • • • • • • • • • • • • • | | | |
| Generic name | Trade name, Manu | ıf. Company, | Strength & | Adult dose | Contraindication |
| | country | | dosage form | e.g. (1x3) | S |
| | original | Other | | | |
| 1 | | | | | ••••• |
| | | | | | |
| | | | | | |
| | | | | | |
| 2 | | | | | |
| | | | | | ••••• |
| | | | | •••• | ••••• |
| | | | | | ••••• |
| 3 | | | | | ••••• |
| 3 | | | | | ••••• |
| | | | | •••• | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| | cal preparations | | | | |
| for Scabies M. | O.A: | | | | |
| ••••• | | | | | |
| ••••• | | | | | |
| 1 | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| | | | | | •••• |
| 2 | | | | | |
| | | | | | |
| | | | | | |
| | | | | | ••••• |
| (xi) Topi | cal proparations fo | r Aona (other the | n | | |
| (XI) I OPI | cal preparations fo | or Ache (other tha | 111 | | |
| antibacterials) N | 1. U. A: | | | | |
| | · · · · · · · · · · · · · · · · · · · | •••• | 1 | I | |
| 1 | | | | | ••••• |
| | | | | •••• | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| 2 | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| 3 | | | | | •••••• |
| | | | | | ••••• |
| | | | | | |
| | | | | | ••••• |
| (xii) Topi | cal preparations fo | or Warts | 1 | 1 | |
| 1 | ear proparations to | - , , 441 60 | | | |
| 1 | | | | | ••••• |
| | | 1 | 1 | | |



| | | | | | N. C. |
|------------|----------------------|--------------|-------|-------|-------------------------------------------|
| | | | | | ••••• |
| | | | | | ••••• |
| (xiii) Med | icated Soaps | | | | |
| 1 | | | | | ••••• |
| | | | | •••• | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| 2 | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| | septics /disinfectan | ts solutions | | | |
| 1 | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| 2 | | | | | ••••• |
| | | | | •••• | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |
| 3 | ••••• | ••••• | ••••• | ••••• | ••••• |
| | ••••• | ••••• | ••••• | •••• | ••••• |
| | | | | | ••••• |
| | | | | | ••••• |



E. OTC for Ear disorders (Ear drops/washes) Task 11: Complete the following table of TOPICAL Otic OTC with different generic

| | mplete the followin | | AL Otic OTC w | ith different g | generic names |
|--------------|---------------------|--------------------|---------------|-----------------|-------------------|
| | drop antibacterial | | | | |
| Generic name | Trade name, Manı | ıf. Company, | Strength & | Adult dose | Contraindications |
| | country | 0.1 | dosage form | e.g. (1x3) | |
| | original | Other | | | |
| 1 | | | | | ••••• |
| | | | | | •••• |
| | | | | | ••••• |
| | | | | | ••• |
| 2 | | | | | ••••• |
| | | | | •••• | •••• |
| | | | | | ••••• |
| 2 | | | | | ••• |
| 3 | | | | | ••••• |
| | | | | | •••• |
| | | | | | ••••• |
| (ii) Ear | drop antifungal (pl | oin) | | | ••• |
| · ' | | am) | | | |
| 1 | | | | | ••••• |
| | | | | | •••• |
| | | | | | ••••• |
| 2 | | | | | ••• |
| 2 | | | | | ••••• |
| | | | | | •••• |
| | | | | | ••••• |
| 3 | | | | | ••• |
| J | | | | ••••• | ••••• |
| | | ••••• | ••••• | •••• | •••• |
| | | | | | ••••• |
| 4 | | | | | ••• |
| т | | | | | ••••• |
| | | | | •••• | •••• |
| | | | | | ••• |
| (iii) Ear | drop : corticostero | id + antibacterial | | I . | |
| 1 | | | | | |
| I | | | | | |
| | | | | | •••• |
| | | | | | ••• |
| 2 | | | | | ••• |
| | | | | | |
| | , | | | | •••• |
| | | | | | ••• |
| 3 | | | | | |
| | | | | | •••• |
| | | | 1 | | |



| | | | | | ••••• | | | |
|----------|---------------|-------|-------|-------|-------|--|--|--|
| | | | | | ••• | | | |
| (iv) Ear | (iv) Ear wash | | | | | | | |
| 1 | | | | | ••••• | | | |
| | | | | | •••• | | | |
| | | | | | ••••• | | | |
| | | | | | ••• | | | |
| 2 | ••••• | ••••• | | ••••• | ••••• | | | |
| | ••••• | ••••• | ••••• | •••• | •••• | | | |
| | | | | | ••••• | | | |
| | | | | | ••• | | | |



F. OTC for Eye disorders (Ear drops, ointments, creams, gels)

Task 12: Complete the following table of TOPICAL Ophthalmic OTC with different generic names

| | | ons; antibacterial (_] | | | |
|--------------|--------------------|-----------------------------------|-----------------------------------------|------------|-----------------------------------------|
| Generic name | Trade name, Man | uf. Company, | Strength & | Adult dose | Contraindications |
| | country | | dosage form | e.g. (1x3) | |
| | original | Other | | | |
| 1 | | | | | • • • • • • • • • • • • • • • • • • • • |
| | | | | | •••• |
| | | | | | |
| | | | | | |
| 2 | | | | | ••• |
| = | | | | | ••••• |
| | | | | •••• | •••• |
| | | | | | ••••• |
| | | | | | ••• |
| 3 | | | | | ••••• |
| | | | | •••• | •••• |
| | | | | | ••••• |
| | | | | | ••• |
| (ii) Oph | thalmic preparatio | ons; corticosteroid | (plain) | | |
| l | | | | | • • • • • • • • • • • • • • • • • • • • |
| | | | | | •••• |
| | | | | | |
| | | | | | ••• |
| 2 | | | | | |
| | | | | | |
| | | | | •••• | •••• |
| | | | | | ••••• |
| , | | | | | ••• |
| 3 | | ••••• | • • • • • • • • • • • • • • • • • • • • | ••••• | ••••• |
| | | | | | •••• |
| | | | | | ••••• |
| | | | | | ••• |
| 4 | | | | | ••••• |
| | | | | | •••• |
| | | | | | ••••• |
| | | | | | ••• |
| (iii) Oph | thalmic preparatio | ons; corticosteroid | + antibacterial | (plain) | |
| L | | | | _ | ••••• |
| | | | | | |
| | | ••••• | ••••• | •••• | •••• |
| | | | | | ••••• |
|) | | | | | ••• |
| 2 | | | | ••••• | ••••• |
| | | | | •••• | •••• |
| | | | | | ••••• |
| | | | | | ••• |
| 3 | | | | | ••••• |
| | | | | | •••• |



| | | | | | ••••• | | | | |
|----------|--------------------------------------------------|-------|-------|-------|-------|--|--|--|--|
| | | | | | ••• | | | | |
| (iv) Oph | (iv) Ophthalmic preparations; for dryness of Eye | | | | | | | | |
| 1 | | | | | ••••• | | | | |
| | | | | | •••• | | | | |
| | | | | | •••• | | | | |
| | | | | | ••• | | | | |
| 2 | ••••• | ••••• | ••••• | ••••• | ••••• | | | | |
| | ••••• | ••••• | ••••• | •••• | •••• | | | | |
| | | | | | •••• | | | | |
| | | | | | ••• | | | | |



G. Nutrients (vitamins & minerals) Task 13: Complete the following table of Nutrie

Task 13: Complete the following table of Nutrient OTC with different generic names

| | le Plain Vitamins ; | | | | |
|----------------------------|---------------------|-------------------|-------------|------------|-----------------------------------------|
| Generic name | Trade name, Man | uf. Company, | Strength & | Adult dose | Contraindications |
| | country | | dosage form | e.g. (1x3) | |
| | original | Other | | | |
| 1 Vitamin C | | | | | |
| oral | | | | | • |
| | | | | | |
| 2 Vitamin C | | | | | |
| injection | | | | | |
| 3 Vitamin A | | | | | |
| oral | | | | | • |
| | | | | | ••••• |
| 4 Vitamin E | | | | | •••• |
| oral | | | | | • |
| ~ - | | | | | • |
| 5 Vitamin D | | | | | |
| oral | | | | | |
| 6 Vitamin D | | | | | |
| injection | | | | | |
| 7 Vitamin B12 | | | | | |
| oral | | | | | |
| 8 vitamin B12 | | | | | |
| o vitamin B12 injection | | | | | |
| | 1 6 | (| | | |
| ` ' | bination of vitami | ns (no minerais) | 1 | I | |
| 1 Vitamin A + | | | | | ••••• |
| E | | | | | • |
| oral | | | | | ••••• |
| 2 Vitamin B1 | | | | | ••••• |
| +B6 + B12 | | | | | • |
| Oral | | | | | ••••• |
| 3 Vitamin B1 | | | | | |
| +B6 + B12 | | | | | |
| injection | | | | | |
| 4 Vitamin B | | | | | •••• |
| complex | | | | | • |
| oral | | | | | • • • • • • • • • • • • • • • • • • • • |
| 5 Vitamin B | | | | | |
| compl | | | | | |
| ex | | | | | |
| | | | | | |
| inject | | | | | |
| ion | | | | | |
| 6 | | | | | ••••• |
| | | | | | • |



| Multivitami ns oral | | | | | |
|------------------------|-------|-------|-------|-------|-------|
| | | | | | ••••• |
| | | | | | • |
| | | | | | ••••• |
| | | | | | ••••• |
| | | | | | • |
| | | | | | ••••• |
| | ••••• | ••••• | ••••• | ••••• | ••••• |
| | ••••• | ••••• | ••••• | •••• | • |
| | | | | | ••••• |



| (iii) Minerals Plain (No vitamins) | | | | | | | |
|-------------------------------------|-----------------------------------------|-----------------------------------------|-------------|------------|-------------------|--|--|
| Generic name | Trade name, Manı | ıf. Company, | Strength & | Adult dose | Contraindications | | |
| | country | | dosage form | e.g. (1x3) | | | |
| | original | Other | | | | | |
| 1 Calcium salts | | | | | | | |
| oral | | | | | •••• | | |
| | | | | | | | |
| | | | | | ••• | | |
| 2 Calcium salts | | | | | | | |
| injection | | | | | •••• | | |
| 111,0001011 | | | | | | | |
| | | | | | | | |
| (iv) Mine | erals with few vitar | ning | | | ••• | | |
| ` / | | 111115 | | | | | |
| 1 Vitamin C + | | • • • • • • • • • • • • • • • • • • • • | ••••• | | ••••• | | |
| Calcium oral | | | | | •••• | | |
| | | | | | ••••• | | |
| | | | | | ••• | | |
| 2 Vitamin C + | | | | | ••••• | | |
| calcium | | | | | •••• | | |
| injection | | | | | ••••• | | |
| | | | | | ••• | | |
| 3 Vitamin A | | | | | ••••• | | |
| + zinc | | | | | •••• | | |
| | | | | | ••••• | | |
| | | | | | ••• | | |
| (v) Mult | tivitamins + minera | als | | | | | |
| Multivitami | | | | | | | |
| ns + | | | | | •••• | | |
| minerals | | | | | ••••• | | |
| | | | | | ••• | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | •••• | | |
| | | | | | ••• | | |
| | | | | | ••• | | |
| | | | | | ••••• | | |
| | • • • • • • • • • • • • • • • • • • • • | | | •••• | •••• | | |
| | | | | | ••••• | | |
| | | | | | ••• | | |
| | | | | | ••••• | | |
| | | | | | •••• | | |
| | | | | | ••••• | | |
| (vri) D | | | | | ••• | | |
| | al jelly ± vitamins | <u> </u> | 1 | I | | | |
| Royal jelly ± | | | | | ••••• | | |
| vitamins | | | | | •••• | | |
| | | | | | ••••• | | |
| | | | | | ••• | | |



| | | | | | ••••• |
|-------------|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|-------|-------|
| | | | | •••• | •••• |
| | | | | | ••••• |
| | | | | | ••• |
| (vii) Gins | eng ± vitamins | | | | |
| Ginsen | | | | | ••••• |
| g ± | | | | •••• | •••• |
| vitamin | | | | | ••••• |
| S | | | | | ••• |
| | | | | | ••••• |
| | | | | •••• | •••• |
| | | | | | ••••• |
| | | | | | ••• |
| (viii) Gins | eng + Royal jelly | ± vitamins | | | |
| Ginseng + | | | | | ••••• |
| Royal jelly | | | | •••• | •••• |
| ± | | | | | ••••• |
| vitamins | | | | | ••• |
| | ••••• | ••••• | ••••• | ••••• | ••••• |
| | ••••• | ••••• | ••••• | •••• | •••• |
| | | | | | ••••• |
| | | I and the second | | | |



| (ix) Antanemics preparations (Folic acid plain) | | | | | | | |
|---------------------------------------------------|-----------------------------------------|----------------------|-----------------------------------------|----------------|------------------|--|--|
| Generic name | Trade name, Manu | ıf. Company, | Strength & | Adult dose | Contraindication | | |
| | country | | dosage form | e.g. (1x3) | S | | |
| | original | Other | | Q (, , | | | |
| Folic acid oral | | | | | ••••• | | |
| | | | | | ••••• | | |
| | | | | | | | |
| | | | | | | | |
| Folic acid | | | | | | | |
| injectable | •••••• | | | | ••••• | | |
| injectubie | | | | •••• | ••••• | | |
| | | | | | ••••• | | |
| (v) Anto | namias nuonaustis | na (ivan nlain) | | | ••••• | | |
| | nemics preparatio | us (iron piain) | 1 | I | | | |
| 1 iron oral | | | | | ••••• | | |
| | | | | •••• | ••••• | | |
| | | | | | ••••• | | |
| | | | | | ••••• | | |
| 2 Iron | | | | | ••••• | | |
| injectable | | | | •••• | ••••• | | |
| | | | | | ••••• | | |
| | | | | | ••••• | | |
| (xi) Anta | nemics preparatio | ns (iron + folic ac | id) | | | | |
| Iron + folic | | | | | | | |
| acid | | | | | ••••• | | |
| aciu | •••••• | | | •••• | ••••• | | |
| | | | | | ••••• | | |
| | | | | | ••••• | | |
| | | | | | ••••• | | |
| | ••••• | | ••••• | •••• | ••••• | | |
| | | | | | ••••• | | |
| | | | | | ••••• | | |
| | | | | | ••••• | | |
| | | | | •••• | ••••• | | |
| | | | | | ••••• | | |
| | | | | | ••••• | | |
| Iron + folic | | | | | ••••• | | |
| acid | | | | | ••••• | | |
| + vitamin C | | | | | ••••• | | |
| | | | | | ••••• | | |
| | • • • • • • • • • • • • • • • • • • • • | ••••• | • • • • • • • • • • • • • • • • • • • • | ••••• | ••••• | | |
| | ••••• | ••••• | ••••• | •••• | ••••• | | |
| | | | | | ••••• | | |
| | | | | | ••••• | | |
| | 1 | | | 1 | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |



Task 14: Nutrient OTC for Specific group of patients (Write generic name)

| OTC for GIT | Pediatric (Child) | Pregnant women | Lactating (breastfeedi ng) women | Renal failure | Hepatic failure | CVS disease | Old people (Geriatric) |
|-------------|----------------------|-------------------|----------------------------------------|--------------------|--------------------|----------------|---------------------------|
| Vitamin A | age | | | Dose adjustment | | | Dose adjustment |
| Vitamin D | age | | | Dose adjustment | | | Dose adjustment |
| Ginseng | age | | | Dose adjustment | | | Dose adjustment |
| Iron | age | | | Dose adjustment | | | Dose adjustment |



IV. PRESCIPTION-ONLY MEDICATIONS (POM_s)

Task 15: Complete the following tables of **POMs for CNS** diseases

| 1. Narcotic analg | gesics | | | |
|---------------------|--------------------|------------------|--------------|-----------------------------------------|
| Generic name | Trade name | Strength/ dosage | adult Dose | Manuf. |
| | | form | (e.g. 1 x3) | Company, |
| | | TOTH | (c.g. 1 x3) | country |
| 1 | | | | ••••• |
| 2 | | | | ••••• |
| 3 | | | | ••••• |
| 2. Antidepressan | its | | | |
| 1 | | | | ••••• |
| 2 | | | | |
| 3 | | | | •••• |
| 4 | | | | ••••• |
| 5 | | | | ••••• |
| 3. Antipsychotics | S | | | |
| 1 | | | | ••••• |
| 2 | | | | ••••• |
| 3 | | | | ••••• |
| 4. Antidepressants | s + antipsychotics | | | |
| 1 | | | | ••••• |
| 2 | | | | ••••• |
| 3 | | | | ••••• |
| 5. Sedatives / hypi | notics | | | |
| 1 | | | | ••••• |
| 2 | | | | ••• |
| 3 | | | | ••• |
| 4 | | | | •••• |
| 6. Antiepileptics | | | | |
| 1 | | | | ••••• |
| 2 | | | | ••• |
| 3 | | | | • • • • • • • • • • • • • • • • • • • • |



Task 16: Complete the following tables of **POMs** for CVS diseases

| | | 1. Diuretics | | |
|--------------------|----------------------------------------|----------------------|-----------------------------------------|----------|
| Generic name | Trade name | Strength/ dosage | adult Dose | Manuf. |
| | | form | (e.g. 1 x3) | Company, |
| | | 101111 | (e.g. 1 x3) | country |
| 1.Hydrochlorothiaz | | | | Country |
| ide | | | | |
| 2 amiodarone | | | | ••••• |
| 3 furosemide | | | | ••••• |
| 4 Toresemide | | | | |
| | 2. | Antihypertensives | | |
| | | (i) Centrally a | cting | |
| Methyldopa | | | | ••••• |
| | (i |) Alpha-blockers | S | |
| 1 Prazosin | | | | ••••• |
| 2 Doxazosin | | | | ••••• |
| | (| ii) Beta blockers | | |
| 1 Propranolol | | | | ••••• |
| 2 Atenolol | | | | ••••• |
| 3 metoprolol | | | | ••••• |
| 4 Bisoprolol | | | | ••••• |
| 5 Carvidolol | | *** | | ••••• |
| | (ì | ii) ACE inhibitors | S | |
| 1 | | | | ••••• |
| 2 | | | | ••••• |
| 3 | ······································ | | • • • • • • • • • • • • • • • • • • • • | ••••• |
| | (iv) | Angiotensin II bloo | ckers | |
| 1 | | | | ••••• |
| 2 | | TO 1 101 4 | | ••••• |
| 4111 | (v) | Direct vasodilate | ors | |
| 1 hydralazine | | | | ••••• |
| | 3. Antıl | nypertensives + diu | retics | |
| 1 | | | | ••••• |
| 2 | | | | ••••• |
| 3 | | | | ••••• |
| •••••• | 4 | Antiarrythmic drugs | <u> </u> | |
| 1 | | | | |
| | | Antihpertensives, ar | ntiarrythmics, and | |
| 1Nifedipine | chamier blockers (| | | |
| 2 Amlodipine | | | | ••••• |
| 3 Dilitiazem | | | | ••••• |
| 4 verapamil | | ••••• | | |
| I | | ********* | | |



| 6. Cardiac stimulants for CHF and cardiac arrest | | | | | | | |
|--------------------------------------------------|--------------------|-------------------|-------------|----------|--|--|--|
| (i) Digitalis | | | | | | | |
| Generic name | Trade name | Strength/ dosage | adult Dose | Manuf. | | | |
| | | form | (e.g. 1 x3) | Company, | | | |
| | | | | country | | | |
| 1 Digoxin | | | | ••••• | | | |
| (ii) Sympathor | nimetics and dopan | ninergic agonists | | | | | |
| Adrenaline | | | | ••••• | | | |
| Dopamine | | | | ••••• | | | |
| Dobutamine | | | | ••••• | | | |
| 7. Antianginals (Coronary vasodilators) | | | | | | | |
| 1 Nitroglycerin | | | | ••••• | | | |
| 2 Isosobide | ••••• | ••••• | ••••• | | | | |

Task 17: Answer the following questions Q1. Which of the CVS drugs are available as injection? Q2. Mention three CVS diseases in which amlodipine can be used? Q3. For pregnant women, which of the above enumerate the CVS drugs that can be used safely? Q4. Mention other drugs used as prophylactic for angina?



Task 18: Complete the following tables of **POMs** for Blood disorders

| 1. Antihemoorha | nge (Hemostatics) | | | |
|---------------------|-------------------|------------------|-------------|-----------------------------------------|
| Generic name | Trade name | Strength/ dosage | adult Dose | Manuf. |
| | | Form | (e.g. 1 x3) | Company, country |
| 1 | | | | ••••• |
| 2 | | | | ••••• |
| 2. Oral Anticoag | ulants | | | |
| 1 | | | | ••••• |
| 2 | | | | • • • • • • • • • • • • • • • • • • • • |
| 3 | | | | • • • • • • • • • • • • • • • • • • • • |
| 3. Injectable antic | oagulants | | | |
| 1 | | | | • • • • • • • • • • • • • • • • • • • • |
| 2 | | | | • • • • • • • • • • • • • • • • • • • • |
| 3, | | ••••• | | ••••• |
| ••••• | | | | |

Task 19 : Complete the following tables of \underline{POMs} \underline{fo} r Bronchial asthma

| 1. Acute asthma | | | | | | | | |
|-------------------|-----------------------------------------|------------------|-------------|----------|--|--|--|--|
| Generic name | Trade name | Strength/ dosage | adult Dose | Manuf. | | | | |
| | | form | (e.g. 1 x3) | Company, | | | | |
| | | | | country | | | | |
| 1 | | | | ••••• | | | | |
| 2 | | | | ••••• | | | | |
| 2. Prophylaxis of | 2. Prophylaxis of asthma | | | | | | | |
| 1 | | | | ••••• | | | | |
| 2 | | | | ••••• | | | | |
| 3 | • • • • • • • • • • • • • • • • • • • • | ••••• | ••••• | ••••• | | | | |



Task 20 : Complete the following tables of $\underline{POMs\ fo}r$ Bacterial infections

| 1.SYSTEMIC ANTIBACTERIALS | | | | | |
|--------------------------------------|------------------------------|-------------------------------------|---------------------------|--------------------|--|
| | (i |) Sulfonamides | + | | |
| Generic name | Trade name | Strength/ dosage form | adult Dose (e.g. 1 x3) | Manuf. Company, | |
| | | 101111 | (e.g. 1 x3) | country | |
| 1 sulfamethoxazole + trimethoprim | | | | | |
| 1 | (ii |) Fluroquinolon | es | | |
| 1 Ciprofloxacin | | | | ••••• | |
| 2 Norfloxacin | | | | ••••• | |
| 3 Ofloxacin | | | | ••••• | |
| 4 Levofloxacin | | | | ••••• | |
| 5 Lomefloxacin | | | | ••••• | |
| | | (<mark>iii) Glycopeptides</mark> | 3 | | |
| 1 Vancomycin | | | | ••••• | |
| | _ | <mark>, clostridium</mark> , anero | | | |
| | aginosis (also are u | sed for amoeba, giard | lia and trichomor | nas) | |
| 1Metronidazole | | | | ••••• | |
| 2 Tinidazole | | | | ••••• | |
| 3 Scendiazole | | | | ••••• | |
| | (iv) | Semisynethetic antil | | | |
| | BETA | ALACTAM (Penicillin cephalosporins) | <u> </u> | | |
| | • | Peneicillins narrow | spectrum | | |
| 1 Crystalline Pn (Pn G) | | | | ••••• | |
| 2 Procaine Pn | | | | ••••• | |
| 3 benzathin Pn | | | | | |
| 4 Phenoxymethyl Pn | | | | ••••• | |
| Pn V) | | | | | |
| | • | Penicillins (broad s | pectrum) | | |
| 1 Ampicillin | | ••••• | | ••••• | |
| 2 Amoxicillin | | | | ••••• | |
| | Penicill | ins (Broad + resistan | t to betalactmase |) | |
| 1 Ampicillin + cloxacillin | | | | ••••• | |
| 2 Amoxicillin + flucloxacillin | | | | ••••• | |
| | Penicillins (F | Extended-spectrum re | sistant to betalac | tmase) | |



| 1 amoxicillin + clavulenic acid | | | | •••••• |
|------------------------------------|--------|--------|-------|--------|
| Piperacilli | | | | ••••• |
| n + | | | | |
| tazobacta | | | | |
| m | | | | |
| Ampicillin + sulbactam | •••••• | •••••• | ••••• | ••••• |



| • Ceph | | | | | | | |
|----------------|----------------------------------|--------------|-------|-----------------------------------------|--|--|--|
| Cefadroxyl | | | | ••••• | | | |
| Cefazoline | | | | ••••• | | | |
| Cefradine | | | | •••• | | | |
| Cefalexin | | | | ••••• | | | |
| • Ceph | alosporins (2 nd gene | eration) | | | | | |
| Cefuroxime | | | | • • • • • • • • • • • • • • • • • • • • | | | |
| Cefprozil | | | | ••••• | | | |
| Cefaclor | | | | ••••• | | | |
| • Ceph | alosporins (3 rd gene | eration) | | | | | |
| Cefpodoxime | | | | ••••• | | | |
| Cefixime | | | | ••••• | | | |
| Ceftriaxone | | | | ••••• | | | |
| Cefotaxime | | | | ••••• | | | |
| Ceftazidime | | | | ••••• | | | |
| | N | MACROLIDES | | | | | |
| Erythromycin | | | | ••••• | | | |
| Clarithromycin | | | | ••••• | | | |
| Azithromycin | | | | ••••• | | | |
| Roxithromycin | | | | ••••• | | | |
| Spiramycin | | | | ••••• | | | |
| | AM | IINOGLYCOSID | | | | | |
| | | ES | | | | | |
| Gentamicin | | | | ••••• | | | |
| Amikacin | | | | ••••• | | | |
| Tobramycin | | | | ••••• | | | |
| LINCOSAMIDES | | | | | | | |
| Lincomycin | | | | ••••• | | | |
| Clindamycin | | | | ••••• | | | |
| | TI | ETRACYCLINS | | | | | |
| Tetracyclin | | | | ••••• | | | |
| Doxycyclin | ••••• | ••••• | ••••• | ••••• | | | |

Task 21: Complete the following table

| | P √ | ut | | Pu t √ | |
|-------------------|--------------|------------------|------------------|----------------|------------------|
| Antibacterials | G +v e | G - v e | Bactericid al | Bacteriostatic | Main indications |
| Sulfonamides + | 0 | 0 | 0 | Ο | |



| Fluroquinolon | 0 | 0 | 0 | 0 | |
|---------------|---|---|---|---|---------|
| es | | | | | |
| Vancomycin | 0 | 0 | 0 | 0 | |
| | | | | | |
| Narrow Pn | 0 | 0 | 0 | 0 | |
| | | | | | |
| Broad Pn | 0 | 0 | 0 | 0 | |
| | | | | | |
| Broad + | 0 | 0 | 0 | 0 | |
| resistant | | | | | |



| Pn | | | | | |
|--------------------|---|---|---|---|-------------|
| Extended- | 0 | 0 | 0 | 0 | |
| resistant Pn | | | | | |
| 1 st | 0 | 0 | 0 | 0 | |
| cephalosporins | | | | | |
| 2 nd | 0 | 0 | 0 | 0 | |
| cephalosporins | | | | | |
| 3 rd | 0 | 0 | 0 | 0 | |
| cephalosporon s | | | | | |
| Aminoglycosid e | 0 | 0 | 0 | 0 | |
| Macrolides | 0 | 0 | 0 | 0 | |
| Lincosamides | 0 | 0 | 0 | 0 | |
| Tetracyclins | 0 | 0 | 0 | 0 | |
| | | 1 | | | |

Task 22: Complete the following tables of **POMs** for Other infections

| 2. SYSTEMIC ANTIFUNGALS | | | | | | | |
|-------------------------|-------------|-----------------------|------------------------|-------------------------------|--|--|--|
| Generic name | Trade name | Strength/ dosage form | adult Dose (e.g. 1 x3) | Manuf. Company, country | | | |
| Fluconazole | | | | ••••• | | | |
| Itraconazole | | | | ••••• | | | |
| Ketoconazole | | | | ••••• | | | |
| | 3. SYS | TEMIC ANTIVIR | RALS | | | | |
| Acyclovir | | | | ••••• | | | |
| ••••• | | | | ••••• | | | |
| ••••• | | | | ••••• | | | |
| ••••• | | | | ••••• | | | |
| ••••• | | | | ••••• | | | |
| 4. SYSTEMIC A | NTIAMOEBIAL | S, ANTIGIARDIA | LS, ANTITRIC | HOMONALS | | | |
| ••••• | | | | ••••• | | | |



| ••••• | | | ••••• |
|-------|-----------------------------------------|------|-----------------------------------------|
| | • • • • • • • • • • • • • • • • • • • • | | • • • • • • • • • • • • • • • • • • • • |



| 5. SYSTEMIC ANTI-TB | | | | | | | |
|---------------------|----------------|-----------------|------------|-----------------------------------------|--|--|--|
| ••••• | | | | ••••• | | | |
| ••••• | | | | ••••• | | | |
| ••••• | | | | ••••• | | | |
| ••••• | | | | ••••• | | | |
| ••••• | | | | ••••• | | | |
| | | | | | | | |
| ••••• | | | | ••••• | | | |
| ••••• | | | | ••••• | | | |
| | 7. SYSTEM | IC ANTI-TOXOPI | ASMOSIS | | | | |
| ••••• | | | | ••••• | | | |
| ••••• | | | | ••••• | | | |
| | 8. ANTHELM | INTICS (COMMO | N WORMS) | | | | |
| ••••• | | | | ••••• | | | |
| ••••• | | | | ••••• | | | |
| ••••• | | | | ••••• | | | |
| | 9 | . ANTI-TEANIA | | | | | |
| ••••• | | | | ••••• | | | |
| ••••• | | | | ••••• | | | |
| ••••• | | | | ••••• | | | |
| 1 | 10. ANTI-BILHA | RIZIALS (ANTISC | CHISTOSOMA |) | | | |
| ••••• | | | | • • • • • • • • • • • • • • • • • • • • | | | |
| ••••• | | | | ••••• | | | |
| •••• | ••••• | ••••• | ••••• | ••••• | | | |



V. PRESCRIPTIONS CHECKING

| Δ | Task 23: | Attach 5 prescriptions you encounter in the pharmacy here | |
|---|----------|-----------------------------------------------------------|--|
| | r r | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |



Provide the following information of the prescription $Prescription \ 1$

| Patient data | | | | | | | | | |
|--------------|---------------|-----------------|----------------|------|----------|----------|--|--|--|
| Age | - | | | | | | | | |
| Sex | - | | | | | | | | |
| Medic | Medications | | | | | | | | |
| No. | Trade Name | Generic name | Dosage form | Dose | quantity | Price YR | | | |
| 1 | | | | | | | | | |
| 2 | | | | | | | | | |
| 3 | | | | | | | | | |
| 4 | | | | | | | | | |
| 5 | | | | | | | | | |
| Check | dose and Drug | interaction (U | se Medscape) | | | | | | |
| | | | | | | | | | |
| - | | | | | | | | | |
| | | | | | | | | | |
| - | - | | | | | | | | |
| | - | | | | | | | | |
| | | | | | | | | | |
| | - | | | | | | | | |



| A 44 - al | ÂL- RAZI UNIVERSITY | |
|----------------------------|---------------------|--|
| Attach prescription 2 here | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |



Provide the following information of the prescription

Prescription 2

| Patient data | | | | | | | |
|--------------|---------------|-----------------|----------------|------|----------|----------|--|
| Age | Age | | | | | | |
| Sex | Sex | | | | | | |
| Medic | ations | | | | | | |
| No. | Trade Name | Generic name | Dosage form | Dose | quantity | Price YR | |
| 1 | | | | | | | |
| 2 | | | | | | | |
| 3 | | | | | | | |
| 4 | | | | | | | |
| 5 | | | | | | | |
| Check | dose and Drug | interaction (U | | | | | |
| | | | | | | | |
| - | | | | | | | |
| - | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |



Attach prescription 3 here

| | 100 |
|--|-----|



Provide the following information of the prescription $Prescription \ 3$

| Patien | it data | | | | | |
|----------|---------------|-----------------|--------------|------|----------|----------|
| Age | Age | | | | | |
| Sex | - | | | | | |
| Medic | ations | | | | | |
| No. | Trade | Generic | Dosage | Dose | quantity | Price YR |
| | Name | name | form | | | |
| 1 | | | | | | |
| 2 | | | | | | |
| <u> </u> | | | | | | |
| 3 | | | | | | |
| | | | | | | |
| 4 | | | | | | |
| | | | | | | |
| 5 | | | | | | |
| | | | | | | |
| Check | dose and Drug | interaction (U | se Medscape) | | | |
| | | | | | | |
| | | | | | | |
| - | | | | | | |
| | | | | | | |
| - | | | | | | |
| | | | | | | |
| - | - | | | | | |
| | | | | | | |
| - | | | | | | |
| | | | | | | |

PHARMACY BACHELOR



Field training Booklet Attach prescription 4 here



Provide the following information of the prescription $Prescription \ 4$

| Patien | t data | | | | | |
|--------|---------------|-----------------|----------------|------|----------|----------|
| Age | | | | | | |
| Sex | - | | | | | |
| Medic | eations | | | | | |
| No. | Trade Name | Generic name | Dosage form | Dose | quantity | Price YR |
| 1 | | | | | | |
| 2 | | | | | | |
| 3 | | | | | | |
| 4 | | | | | | |
| 5 | | | | | | |
| Check | dose and Drug | interaction (U | se Medscape) | | | |
| | | | | | | |
| | | | | | | |
| - | | | | | | |
| | | | | | | |
| - | | | | | | |
| - | - | | | | | |
| | | | | | | |
| | | | | | | |



| prescription 5 here | | |
|---------------------|--|--|
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |



Provide the following information of the prescription Prescription 5

| Patient data | | | | | | | |
|--------------|---------------|-----------------|----------------|------|----------|----------|--|
| Age | Age | | | | | | |
| Sex | Sex | | | | | | |
| Medic | eations | | | | | | |
| No. | Trade Name | Generic name | Dosage form | Dose | quantity | Price YR | |
| 1 | | | | | | | |
| 2 | | | | | | | |
| 3 | | | | | | | |
| 4 | | | | | | | |
| 5 | | | | | | | |
| Check | dose and Drug | interaction (U | se Medscape) | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| - | | | | | | | |
| - | | | | | | | |
| | | | | | | | |



VI. PHARMACEUTICAL AGENTS/MANUFACTURERS

Task 25: complete the following table of pharmaceutical manufacturer and agents in Yemen

| الاصناف | الشركات الوكلاء للامناف | عنوان – | اسم الوكيل | م |
|---------|-------------------------|---------|-------------------|---|
| | | تلفون | | |
| 1 | | ••••• | ناتكو(هايل سعيد) | 1 |
| 2 | ••• | •••• | , , " , , | |
| 3 | | ••••• | | |
| 4 | | •••• | | |
| 5 | | ••••• | | |
| •••• | | •••• | | |
| 1 | | ••••• | الفتح | 2 |
| 2 | ••• | •••• | | |
| 3 | | ••••• | | |
| 4 | | •••• | | |
| 5 | | ••••• | | |
| •••• | | •••• | | |
| 1 | | ••••• | الرشيد | 3 |
| 2 | | •••• | | |
| 3 | | ••••• | | |
| 4 | | •••• | | |
| 5 | | ••••• | | |
| •••• | | •••• | | |
| 1 | | ••••• | الجبل | 4 |
| 2 | | •••• | | |
| 3 | | | | |
| 4 | | | | |
| 5 | | | | |
| •••• | | | 114 5 11 | |
| 1 | | ••••• | الغزالي | 5 |
| 2 | | •••• | | |
| 3 | | | | |
| 4 | | | | |
| 5 | | | | |
| •••• | | | | |
| 1 | ••••• | ••••• | العريب | 6 |
| 2 | ••••• | •••• | | |
| 3 | ••••• | | | |



وكلاء اخرين

| أهم الاصناف | الشركات الوكيلة | عنوان ـ تلفون | اسم الوكيل | م |
|-------------|-----------------|---------------|------------|---|
| | | | | |
| 1 | | ••••• | | 1 |
| | | •••• | | |
| 2 | | ••••• | | |
| 3 | | •••• | | |
| 3 | | ••••• | | |
| 4 | | •••• | | |
| 5 | | | | |
| •••• | | | | |
| 1 | | | | 2 |
| | ••• | •••• | | _ |
| 2 | | ••••• | | |
| | | •••• | | |
| 3 | | ••••• | | |
| | | •••• | | |
| 4 | | | | |
| 5 | | | | |
| •••• | | | | 2 |
| 1 | | ••••• | | 3 |
| 2 | | •••• | | |
| 2 | | ••••• | | |
| 3 | | •••• | | |
| | | | | |
| 4 | | - | | |
| 5 | | | | |
| •••• | | | | |
| 1 | | ••••• | | 4 |
| | | •••• | | |
| 2 | | | | |
| 3 | | | | |
| 4 | | | | |
| 5 | | | | |
| •••• | | | | |



مصانع الادوية اليمنية:

| أهم الاصناف | أهم الشركات | عنوان ـ تلفون | اسم المصنع | م |
|-------------|-------------|---------------|------------|---|
| | الوكيلة | | | |
| 1 | | | | 1 |
| | ••• | •••• | | - |
| 2 | | | | |
| | | •••• | | |
| 3 | | ••••• | | |
| 4 | | •••• | | |
| 5 | | | | |
| 5 | | | | |
| 1 | | | | 2 |
| 1 | | | | - |
| 2 | | ••••• | | |
| | | •••• | | |
| 3 | | ••••• | | |
| | | •••• | | |
| 4 | | | | |
| 5 | | | | |
| 1 | | | | 3 |
| 1 | •••••• | ••••• | | 3 |
| 2 | | •••• | | |
| | | •••• | | |
| 3 | | ••••• | | |
| | | •••• | | |
| 4 | | | | |
| 5 | | | | |
| •••• | | | | 4 |
| 1 | ••••• | ••••• | | 4 |
| 2 | | •••• | | |
| 3 | | | | |
| 4 | | | | |
| 5 | | | | |
| •••• | | | | |
| 1 | | •••• | | 5 |
| | | •••• | | |
| 2 | | | | |
| 3 | | | | |
| 4 | | | | |
| 5 | | | | |
| 1 | | | | 6 |
| 1 | | | | U |
| 2 | | •••• | | |
| 3 | | | | |
| 4 | | | | |
| | | <u> </u> | | |



| 5 | | |
|------|-----------|---|
| 3 | | |
| •••• | | |
| 1 | ••••• | 7 |
| | •••• | |
| 2 | | |
| 3 | | |
| 4 | | |
| 5 | | |
| •••• | | |
| 1 | ••••• | 8 |
| | •••• | |
| 2 | | |
| 3 | | |
| 4 | | |
| 5 | | |
| •••• | | |

END OF TRAINING





+967-774440012 - +967-1-216923 🙃

alraziuni.edu.ye ()
alraziuni.edu.ye ()
www.alraziuni.edu.ye ()

